$3.41
7.72% today
Nasdaq, Apr 03, 06:48 pm CET
ISIN
US83422E1055
Symbol
SLDB
Sector
Industry

Solid Biosciences Inc. Stock price

$3.69
-1.43 27.93% 1M
-2.93 44.26% 6M
-0.31 7.75% YTD
-8.41 69.50% 1Y
-14.91 80.16% 3Y
-29.61 88.92% 5Y
-335.61 98.91% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+0.25 7.11%
ISIN
US83422E1055
Symbol
SLDB
Sector
Industry

Key metrics

Market capitalization $285.95m
Enterprise Value $161.21m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.09
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-129.73m
Free Cash Flow (TTM) Free Cash Flow $-100.67m
Cash position $148.92m
EPS (TTM) EPS $-3.04
P/E forward negative
Short interest 12.04%
Show more

Is Solid Biosciences Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Solid Biosciences Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Solid Biosciences Inc. forecast:

12x Buy
100%

Analyst Opinions

12 Analysts have issued a Solid Biosciences Inc. forecast:

Buy
100%

Financial data from Solid Biosciences Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 2.46 2.46
17% 17%
-
-2.46 -2.46
17% 17%
-
- Selling and Administrative Expenses 28 28
30% 30%
-
- Research and Development Expense 96 96
26% 26%
-
-127 -127
26% 26%
-
- Depreciation and Amortization 2.46 2.46
17% 17%
-
EBIT (Operating Income) EBIT -130 -130
24% 24%
-
Net Profit -125 -125
30% 30%
-

In millions USD.

Don't miss a Thing! We will send you all news about Solid Biosciences Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Solid Biosciences Inc. Stock News

Neutral
GlobeNewsWire
2 days ago
CHARLESTOWN, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 43,374 restricted stock units (“RSUs”) to three newly hired employees.
Negative
New York Post
3 days ago
Shares of U.S. drugmakers fell on Monday after reports that the Food and Drug Administration's top vaccine official was forced to resign, the most high-profile exit at the regulator as the Trump administration undertakes an overhaul of federal health agencies.
Neutral
GlobeNewsWire
22 days ago
CHARLESTOWN, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, will present data from the Phase 1/2 INSPIRE DUCHENNE trial evaluating SGT-003, a next-generation gene therapy product candidate intended for the treatment of Duchenne muscular dystrophy (Duchenne), a...
More Solid Biosciences Inc. News

Company Profile

Solid Biosciences, Inc. engages in the development of treatments for patients with Duchenne muscular dystrophy. It develops gene therapies, disease modifying therapies, and assistive devices for the cure of DMD. The company was founded by Ilan Ganot, Andrey J. Zarur, Matthew Arnold, Annie Ganot and Gilad David Hayeem in March 2013 and is headquartered in Cambridge, MA.

Head office United States
CEO Alexander Cumbo
Employees 100
Founded 2013
Website www.solidbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today